Physician profile
Loveneet Singh
NPI 1952560377
$13,359.93
in general payments reported to CMS, 2019-2025
66 companies · $1,830 in 2025
The $1,830 reported for 2025 was more than what a typical Clinical Neurophysiology provider received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,631 · 2020: $1,509 · 2021: $1,977 · 2022: $2,207 · 2023: $2,072 · 2024: $2,133 · 2025: $1,830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,035 · Education: $0.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,034.88 |
| Education | $0.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,249.41 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Acadia Pharmaceuticals INC | $916.19 | 2019-2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $746.07 | 2019-2025 | Ultomiris |
| Sk Life Science, INC. | $731.55 | 2020-2025 | |
| Abbvie INC. | $627.31 | 2020-2025 | Qulipta, Duopa, Ubrelvy |
| Eisai INC. | $558.56 | 2019-2025 | |
| Biogen, INC. | $557.08 | 2019-2025 | Tysabri, Vumerity, Skyclarys |
| Neurocrine Biosciences, INC. | $553.29 | 2020-2025 | Ingrezza, Ongentys |
| Emd Serono, INC. | $450.40 | 2019-2025 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $440.18 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Catalyst Pharmaceuticals, INC. | $416.64 | 2020-2024 | Fycompa |
| Argenx US, INC. | $409.88 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Amneal Pharmaceuticals LLC | $397.88 | 2019-2024 | Rytary, Crexont |
| Sunovion Pharmaceuticals INC. | $391.80 | 2019-2022 | |
| Mdd US Operations, LLC | $381.42 | 2021-2025 | Gocovri, Qelbree |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loveneet Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.